US7538108 — Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Method of Use · Assigned to Rigel Pharmaceuticals Inc · Expires 2026-03-28 · 0y expired
What this patent protects
This patent protects prodrugs of biologically active 2,4-pyrimidinediamine compounds and their uses, including treatment of autoimmune diseases.
USPTO Abstract
The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds of structural formula shown below, compositions comprising these compounds, intermediates and methods for synthesizing these compounds, and methods of using these compounds in a variety of applications including treatment of autoimmune diseases.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-2294 |
— | fostamatinib-disodium |
U-2294 |
— | fostamatinib-disodium |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.